NDLI: A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

Content Provider	PubMed Central
Author	Hall, V. Kairisto, V. Van Der Velden, V. H. J. White, H. Deprez, L. Corbisier, P. Lin, F. Mazoua, S. Trapmann, S. Aggerholm, A. Andrikovics, H. Akiki, S. Barbany, G. Boeckx, N. Bench, A. Catherwood, M. Cayuela, J-m Chudleigh, S. Clench, T. Colomer, D. Daraio, F. Dulucq, S. Farrugia, J. Fletcher, L. Foroni, L. Ganderton, R. Gerrard, G. Gineikienė, E. Hayette, S. Housni, H. El Izzo, B. Jansson, M. Johnels, P. Jurcek, T. Kizilors, A. Kim, D-w Lange, T. Lion, T. Polakova, K. M. Martinelli, G. Mccarron, S. Merle, P. A. Milner, B. Mitterbauer-hohendanner, G. Nagar, M. Nickless, G. Nomdedéu, J. Nymoen, D. A. Leibundgut, E. O. Ozbek, U. Pajič, T. Pfeifer, H. Preudhomme, C. Raudsepp, K. Romeo, G. Sacha, T. Talmaci, R. Touloumenidou, T. Waits, P. Wang, L. Wilkinson, E. Wilson, G. Wren, D. Zadro, R. Ziermann, J. Zoi, K. Müller, M. C. Hochhaus, A. Schimmel, H. Cross, N. C. P. Emons, H.
Copyright Year	2015
Abstract	Serial quantification of BCR–ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of BCR–ABL1 (e14a2 mRNA fusion), BCR and GUSB transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 106, 1.08±0.11 × 105, 1.03±0.10 × 104, 1.02±0.09 × 103, 1.04±0.10 × 102 and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 BCR–ABL1 testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 BCR–ABL1 and three control genes (ABL1, BCR and GUSB). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f).
Related Links	http://dx.doi.org/10.1038/leu.2014.217
Ending Page	376
Page Count	8
Starting Page	369
File Format	PDF
ISSN	08876924
e-ISSN	14765551
Journal	Leukemia
Issue Number	2
Volume Number	29
Language	English
Publisher	Nature Publishing Group
Publisher Date	2015-02-01
Access Restriction	Open
Rights Holder	Nature Publishing Group
Subject Keyword	Anesthesiology and Pain Medicine Cancer Research Hematology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Hematology Cancer Research Anesthesiology and Pain Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale

SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-likedisease and for normal hematopoietic stem cell function

Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia

A Coiled-Coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-Mutant Chronic Myeloid Leukemia

BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

Monoubiquitinated Fanconi Anemia D2 (FANCD2-Ub) Is Required for BCR-ABL1 Kinase -Induced Leukemogenesis

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

Similar Documents

Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale

SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-likedisease and for normal hematopoietic stem cell function

Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia

A Coiled-Coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-Mutant Chronic Myeloid Leukemia

BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

Monoubiquitinated Fanconi Anemia D2 (FANCD2-Ub) Is Required for BCR-ABL1 Kinase -Induced Leukemogenesis

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR